Alpine Immune Sciences Announces Participation in September Investor Conferences

Rhea-AI Summary

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced that its management team will participate in investor conferences in September 2022. Key events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 a.m. PT, featuring a presentation by Chief Business Officer Remy Durand, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, focused on one-on-one meetings. A link to the H.C. Wainwright presentation will be available on the company's investor relations website.

Positive

• Participation in notable investor conferences enhances visibility and investor engagement.
• Opportunity for one-on-one meetings may attract interest and investment opportunities.

Negative

• None.

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced members of its management team will participate at the following investor conferences in September 2022.

H.C. Wainwright 24^th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: 7:00 a.m. PT/10:00 a.m. ET
Event: Corporate Presentation & One-on-One Investor Meetings
Presenter: Remy Durand, PhD, Chief Business Officer, Alpine Immune Sciences, Inc.

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Event: One-on-One Investor Meetings

A link to the H.C. Wainwright corporate presentation will be available online in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and will be available on the Company website for 90 days following the webcast. Investors interested in participating in One-on-One meetings at these conferences should reach out to their sales representatives at H.C. Wainwright and Morgan Stanley for more information.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906006039/en/

Investors

Temre Johnson

Alpine Immune Sciences, Inc.

ir@alpineimmunesciences.com

Media

Kelli Perkins

Red House

kelli@redhousecomms.com

Source: Alpine Immune Sciences Inc.

FAQ

What is the date of the H.C. Wainwright conference where Alpine Immune Sciences will present?

The H.C. Wainwright conference will take place on September 12, 2022.

Who from Alpine Immune Sciences is presenting at the H.C. Wainwright conference?

Remy Durand, PhD, Chief Business Officer, will present at the H.C. Wainwright conference.

Is Alpine Immune Sciences participating in any other conferences in September 2022?

Yes, Alpine will also participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022.

Where can I find the link to the Alpine Immune Sciences presentation?

The link to the presentation will be available in the investor relations section of Alpine's website.

What is the stock symbol for Alpine Immune Sciences?

The stock symbol for Alpine Immune Sciences is ALPN.